EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen access · CC BY 4.0

Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO ‐ TTRansform Trial

Julian D Gillmore iD, David Adams iD, Markus Weiler iD, Ahmad Masri, Laura Obici, Jonatan Nåtman, T Jesse Kwoh, Barry Reicher, James Revkin, Márcia Waddington Cruz, Morie Gertz iD, Chi-Chao Chao

European Journal of Neurology · 2026-04 · 33 (4)

DOI: 10.1111/ene.70580 ↗

At a glance

Randomisierte kontrollierte Studie in European Journal of Neurology, published online on 2026-03-30. Written by Julian D Gillmore and 11 co-authors. Institution: National Amyloidosis Centre, University College London, London, UK. Major MEDLINE topics: Amyloid Neuropathies, Familial, Prealbumin, Polyneuropathies. 31 references. The full text is freely available (open access, CC BY 4.0). Funded by: AstraZeneca.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

This exploratory analysis of the NEURO‐TTRansform Phase 3 trial evaluated the efficacy of eplontersen in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy by genetic variant.

Methods

Changes from baseline in NEURO‐TTRansform primary endpoints serum transthyretin (TTR) at Week 65, modified Neuropathy Impairment Score+7 (mNIS+7) composite score, and Norfolk Quality of Life‐Diabetic Neuropathy (Norfolk QoL‐DN) total score at Week 66 were evaluated in patients with early‐onset (aged < 50 years) and late‐onset (aged ≥ 50 years) Val30Met (p.Val50Met) or non‐Val30Met ATTRv amyloidosis with polyneuropathy. Secondary endpoints from NEURO‐TTRansform were also evaluated by genetic variant.

Results

In total, 144 patients with early‐onset ( n = 54) or late‐onset ( n = 31) Val30Met or non‐Val30Met ( n = 59), ATTRv amyloidosis with polyneuropathy were randomized to eplontersen. A further 60 patients from NEURO‐TTR with early‐onset ( n = 16) or late‐onset ( n = 17) Val30Met or non‐Val30Met ( n = 27), served as a historical placebo group. The mean percentage difference (95% confidence interval) in serum TTR was −79.9 (−87.8, −72.0), −85.0 (−93.3, −76.6), and −70.6 (−77.7, −63.5) with eplontersen versus placebo in the early‐ and late‐onset Val30Met, and non‐Val30Met groups, respectively. Across subgroups, the change from baseline to Week 66 in mNIS+7 composite score was generally well maintained, and the Norfolk QoL‐DN total score improved with eplontersen versus worsening with placebo. The Polyneuropathy Disability score was maintained in most patients. From baseline to Week 65, the modified body mass index was maintained with eplontersen compared to a marked reduction (worsening) for placebo.

Conclusions

Findings were suggestive of consistent benefits in reducing neuropathy impairment and improving QoL with eplontersen versus historical placebo, across TTR variants. Trial Registration ClinicalTrials.gov: NCT04136184, NCT01737398

Subjects

MeSH terms (MEDLINE)

Amyloid Neuropathies, FamilialPrealbuminPolyneuropathiesHumansMiddle AgedFemaleMaleAgedAdultTreatment OutcomeOligonucleotides

Author keywords

ATTR amyloidosisATTRv‐PNVal30Meteplontersenpolyneuropathyquality of life

Substances

PrealbuminInoterseneplontersenOligonucleotides

Authors and institutions

  • National Amyloidosis Centre, University College London, London, UK.
  • Neurology Department, CHU de Bicêtre, AP-HP, Université Paris-Saclay, Le-Kremlin-Bicêtre, France.
  • Amyloidosis Center and Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
  • Oregon Health & Science University, Portland, Oregon, USA.
  • Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
  • BioPharmaceuticals Business Unit, AstraZeneca, Gothenburg, Sweden.

ORCID profiles: Julian D Gillmore, David Adams, Markus Weiler, Morie Gertz

Funding

  • AstraZeneca

Cite

APA

Gillmore, J. D., Adams, D., Weiler, M., Masri, A., Obici, L., Nåtman, J., Kwoh, T. J., Reicher, B., Revkin, J., Cruz, M. W., Gertz, M., & Chao, C. C. (2026). Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO ‐ TTRansform Trial. European Journal of Neurology, 33(4). https://doi.org/10.1111/ene.70580

Vancouver

Gillmore JD, Adams D, Weiler M, Masri A, Obici L, Nåtman J, et al. Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO ‐ TTRansform Trial. European Journal of Neurology. 2026;33(4). doi:10.1111/ene.70580

BibTeX
@article{Gillmore2026,
  author = {Gillmore, Julian D and Adams, David and Weiler, Markus and Masri, Ahmad and Obici, Laura and Nåtman, Jonatan and Kwoh, T Jesse and Reicher, Barry and Revkin, James and Cruz, Márcia Waddington and Gertz, Morie and Chao, Chi-Chao},
  title = {Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO ‐ TTRansform Trial},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {4},
  doi = {10.1111/ene.70580}
}
Start for free →